

(i) a nucleic acid of ORF-1 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MEQAPEDQGPQREPHNEWTLLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDT
WAGVEAIIRILQQLLFIHFRIGCRHSRIGVTQRRRANGASRS,

(ii) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MQPIQIAIAALVVAIIIAIVVWSIVIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS
ALVEMGVEMGHHAPWDIDDL, and

(iii) a nucleic acid of ORF-R of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAAT
NAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDI
LDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWICYKLVPVEPDKVEEANKGENTSLLH
PVSLHGMDDPEREVLEWRFD SRLAFHHVARELHPEYFKNC; and

(b) detecting the formation of hybrids between said one or more nucleic acid probes and nucleic acid present in said biological sample.

36. (NEW) The method according to claim 35, wherein said probe is labeled with a label selected from the group consisting of a radioactive label, an enzymatic label, and a fluorescent label.

37. (NEW) An *in vitro* diagnostic method for detecting the presence or absence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(a) contacting said biological sample with one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-1 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDT
WAGVEAIIRILQQLLFIFRIGCRHSRIGVTQQRARNGASRS and

(ii) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MQPIQIAIAALVVAIIIAIVVWSIVIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS
ALVEMGVEMGHHAPWDIDDL; and

(b) detecting the formation of hybrids between said one or more nucleic acid probes and nucleic acid present in said biological sample.

38. (NEW) The method according to claim 37, wherein said probe is labeled with a label selected from the group consisting of a radioactive label, an enzymatic label, and a fluorescent label.

39. (NEW) An *in vitro* diagnostic method for detecting the presence or absence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:

(a) contacting said biological sample with one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

MQPIQIAIALVVAIIIAIVVWSIVIIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS
ALVEMGVEMGHHAPWDIDDL and

(ii) a nucleic acid of ORF-R of Human Immunodeficiency Virus Type 1
(HIV-1) encoding the amino acid sequence:

MGGKWSKSSVVGWPTVRERMRRRAEPAADGVGAASRDLEKHGAITSSNTAAT
NAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDI
LDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWICYKLVPEPDKVEEANKGENTSLLH
PVSLHGMDDPEREVLEWRFD SRLAFHHVARELHPEYFKNC; and

(b) detecting the formation of hybrids between said one or more nucleic acid
probes and nucleic acid present in said biological sample.

40. (NEW) The method according to claim 39, wherein said probe is labeled
with a label selected from the group consisting of a radioactive label, an enzymatic
label, and a fluorescent label.

41. (NEW) An *in vitro* diagnostic kit for detecting the presence or absence of
nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample
comprising:

(a) a composition comprising one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-1 of Human Immunodeficiency Virus Type 1
(HIV-1) encoding the amino acid sequence:

MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDT
WAGVEAIIRILQQLLFHFRIGCRHSRIGVTQRRARNGASRS,

(ii) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1
(HIV-1) encoding the amino acid sequence:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

MQPIQIAIAALVVAIIIAIVVWSIVIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS
ALVEMGVEMGHHAPWDIDDL, and

(iii) a nucleic acid of ORF-R of Human Immunodeficiency Virus Type 1
(HIV-1) encoding the amino acid sequence:

MGGKWSKSSVVGWPTVRERMRRRAEPAADGVGAASRDLEKHGAITSSNTAAT
NAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDI
LDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWICYKLVPEPDKVEEANKGENTSLLH
PVSLHGMDDPEREVLEWRFD SRLAFHHVARELHPEYFKNC;

(b) reagents for detecting the hybrids; and

(c) a biological reference sample lacking nucleic acid recognized by said
nucleic acid probe composition.

41. (NEW) The kit according to claim 41, wherein said probe is labeled with a
label selected from the group consisting of a radioactive label, an enzymatic label, and a
fluorescent label.

43. (NEW) An *in vitro* diagnostic kit for detecting the presence or absence of
nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample
comprising:

(a) a composition comprising one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-1 of Human Immunodeficiency Virus Type 1
(HIV-1) encoding the amino acid sequence:

MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDT
WAGVEAIIIRILQQLLFHFRIGCRHSRIGVTQQRRARNGASRS and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(ii) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MQPIQIAIAALVVAIIIAIVVWSIVIIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS
ALVEMGVEMGHHAPWDIDDL;

(b) reagents for detecting the hybrids; and

(c) a biological reference sample lacking nucleic acid recognized by said nucleic acid probe composition.

44. (NEW) The kit according to claim 43, wherein said probe is labeled with a label selected from the group consisting of a radioactive label, an enzymatic label, and a fluorescent label.

45. (NEW) An *in vitro* diagnostic kit for detecting the presence or absence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:

(a) a composition comprising one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MQPIQIAIAALVVAIIIAIVVWSIVIIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS
ALVEMGVEMGHHAPWDIDDL and

(ii) a nucleic acid of ORF-R of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAAT
NAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDI

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com